NCT00479349

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Young Male and Elderly Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Male
• Age: 20 Years
• Healthy volunteers: Accepted

Summary

To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy Japanese young male and elderly subjects.To provide the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy Japanese young male and elderly subjects.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	SAM-531	Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.

Timeline

• Start date: 2007-05-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2007-05-28
• Last updated: 2009-07-07

Locations

1 site across 1 country: Japan